✨
AI Summary
- Survodutide, a dual GLP-1/glucagon agonist, demonstrated superior weight loss versus placebo.
- The drug improved blood sugar control in patients with obesity and type 2 diabetes.
- Survodutide also significantly reduced liver fat, a key complication of T2D.